25m
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback